Evidence map›Paper›PMID 33299990›Full record

ArticlebioRxiv : the preprint server for biology2020

Repurposing the Ebola and Marburg Virus Inhibitors Tilorone, Quinacrine and Pyronaridine: In vitro Activity Against SARS-CoV-2 and Potential Mechanisms.

Ana C Puhl, Ethan James Fritch, Thomas R Lane, Longping V Tse, Boyd L Yount, Carol Queiroz Sacramento, Tatyana Almeida Tavella, Fabio Trindade Maranhão Costa, Stuart Weston, James Logue and 14 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 20 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

24 authors at 8 institutions in 2 countries.

Ana C PuhlCollaborations Pharmaceuticals, Inc., 840 Main Campus Drive, Lab 3510, Raleigh, NC 27606, USA.
Ethan James FritchDepartment of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill NC 27599, USA.
Thomas R LaneCollaborations Pharmaceuticals, Inc., 840 Main Campus Drive, Lab 3510, Raleigh, NC 27606, USA.
Longping V TseDepartment of Epidemiology, University of North Carolina School of Medicine, Chapel Hill NC 27599, USA.
Boyd L YountDepartment of Epidemiology, University of North Carolina School of Medicine, Chapel Hill NC 27599, USA.
Carol Queiroz SacramentoLaboratório de Imunofarmacologia, Instituto Oswaldo Cruz (IOC), Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, RJ, Brazil.
Tatyana Almeida TavellaLaboratory of Tropical Diseases - Prof. Dr. Luiz Jacinto da Silva, Department of Genetics, Evolution, Microbiology and Immunology, University of Campinas-UNICAMP, Campinas, SP, Brazil.
Fabio Trindade Maranhão CostaLaboratory of Tropical Diseases - Prof. Dr. Luiz Jacinto da Silva, Department of Genetics, Evolution, Microbiology and Immunology, University of Campinas-UNICAMP, Campinas, SP, Brazil.
Stuart WestonDepartment of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
James LogueDepartment of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Matthew FriemanDepartment of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Lakshmanane PremkumarDepartment of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill NC 27599, USA.
Kenneth H PearceCenter for Integrative Chemical Biology and Drug Discovery, Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina 27599, USA.
Brett L HurstInstitute for Antiviral Research, Utah State University, Logan, UT, USA.
Carolina Horta AndradeLaboratory of Tropical Diseases - Prof. Dr. Luiz Jacinto da Silva, Department of Genetics, Evolution, Microbiology and Immunology, University of Campinas-UNICAMP, Campinas, SP, Brazil.
James A LeviDepartment of Biological Sciences, North Carolina State University, Raleigh, NC, USA.
Nicole J JohnsonDepartment of Biological Sciences, North Carolina State University, Raleigh, NC, USA.
Samantha C KisthardtDepartment of Biological Sciences, North Carolina State University, Raleigh, NC, USA.
Frank ScholleDepartment of Biological Sciences, North Carolina State University, Raleigh, NC, USA.
Thiago Moreno L SouzaLaboratório de Imunofarmacologia, Instituto Oswaldo Cruz (IOC), Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, RJ, Brazil.
Nathaniel John MoormanDepartment of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill NC 27599, USA.
Ralph S BaricDepartment of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill NC 27599, USA.
Peter MadridSRI International, 333 Ravenswood Avenue, Menlo Park, CA 94025, USA.
Sean EkinsCollaborations Pharmaceuticals, Inc., 840 Main Campus Drive, Lab 3510, Raleigh, NC 27606, USA.
University of North Carolina at Chapel Hill · USNorth Carolina State University · USCollaborations Pharmaceuticals (United States) · USUniversidade Estadual de Campinas (UNICAMP) · BRUniversity of Maryland, Baltimore · USFundação Oswaldo Cruz · BRSRI International · USUtah State University · US

Funding

Project 4 - Influenza - UABU19AI142759 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI PAINTER, GEORGE ROBERT · 2019 to 2023
$37.5M
Determinants of Coronavirus Fidelity in Replication and PathogenesisR01AI108197 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BARIC, RALPH S, DENISON, MARK R · 2013 to 2022
$6.5M
Centralized assay datasets for modelling support of small drug discovery organizationsR44GM122196 · NIGMS · COLLABORATIONS PHARMACEUTICALS, INC. · PI EKINS, SEAN · 2018 to 2022
$3.3M
MegaPredict for predicting natural product uses and their drug interactionsR43AT010585 · NCCIH · COLLABORATIONS PHARMACEUTICALS, INC. · PI EKINS, SEAN · 2019 to 2020
$225k
NCCIH NIH HHS R43 AT010585NIAID NIH HHS R01 AI108197NIAID NIH HHS U19 AI142759NIGMS NIH HHS R44 GM122196
6 · The paper itself

Abstract

SARS-CoV-2 is a newly identified virus that has resulted in over 1.3 M deaths globally and over 59 M cases globally to date. Small molecule inhibitors that reverse disease severity have proven difficult to discover. One of the key approaches that has been widely applied in an effort to speed up the translation of drugs is drug repurposing. A few drugs have shown

Identifiers

PMID33299990
PMCPMC7724658
OpenAlexW3107821103

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.